Erin D. Michos, MD, MHS, discusses the clinical implications of select studies presented at the American College of Cardiology 2024 Scientific Session, focusing on late-breaking abstracts in lipid management. In highlighting the VICTORION-INITIATE trial, which demonstrated reductions in LDL through upfront inclisiran therapy, Dr Michos advocates for proactive approaches to address clinical barriers in day-to-day lipid management.
A subgroup analysis of the CLEAR Outcomes trial addressed another treatment gap concerning statin intolerance, demonstrating the efficacy of bempedoic acid across diverse populations, including women, Hispanic/Latinx individuals, and those with obesity. In addition, the TACTiC trial suggested the potential for over-the-counter statins, presenting a novel approach to expand access to lipid-lowering therapy and reduce cardiovascular risk.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ACC 2024: Clinical Impact of New Data in Lipid Management - Medscape - Apr 30, 2024.
Comments